Integrated BioTherapeutics to develop vaccine
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has asked Integrated BioTherapeutics Inc. to develop a vaccine that protects against Ebola and Marburg viruses.
The Germantown-based company will get $22 million under the multiyear contract, and if options are exercised, could get $65 million.
Ebola and Marburg, which are considered bioterrorist threats, lead to death 30 percent to 90 percent of the time that they are contracted, and there are currently no vaccines or therapeutics to treat infected humans.